Cellectis SA (CLLS) ADS Each Repr 1 Ord Spon

Sell:$1.54Buy:$1.81$0.09 (5.77%)

NASDAQ:1.35%
Market closed | Prices delayed by at least 15 minutes
Sell:$1.54
Buy:$1.81
Change:$0.09 (5.77%)
Deal now
Market closed | Prices delayed by at least 15 minutes
Sell:$1.54
Buy:$1.81
Change:$0.09 (5.77%)
Market closed | Prices delayed by at least 15 minutes
Deal now

Company Information

About this company

Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.

Key people

Andre Choulika
Chief Executive Officer, Co-Founder, Director
David Sourdive
Deputy Chief Executive Officer, Co-Founder, Executive Vice President - CMC and Manufacturing, Director
Arthur Stril
Interim Chief Financial Officer
Kyung Nam-Wortman
Chief Human Resource Officer, Executive Vice President
Steven Doares
Senior Vice President - US Manufacturing
Philippe Duchateau
Chief Scientific Officer
Stephan Reynier
Chief Regulatory and Pharmaceutical Compliance Officer
Marie-Bleuenn Terrier
General Counsel
Adrian Kilcoyne
Chief Medical Officer
Jean-Pierre Garnier
Non-Executive Independent Chairman of the Board
Laurent Arthaud
Non-Executive Director
Pierre Bastid
Non-Executive Independent Director
Donald A. Bergstrom
Non-Executive Independent Director
Rainer J. Boehm
Non-Executive Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    France
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US15117K1034
  • Market cap
    $112.06m
  • Employees
    235
  • Shares in issue
    72.09m
  • Exchange
    Euronext Paris
  • Index
  • Website
    Visit website

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.